INDIA – Akums Drugs & Pharmaceutical Limited and Fermenta Biotech Limited (FBL) have teamed up to develop a novel nipple cream for breastfeeding mothers.
Akums, the largest contract-manufacturing pharmaceutical company in India, and Fermenta Biotech have signed an exclusive manufacturing and distribution agreement to market the first-of-its-kind Areola cream for lactating mothers in India and globally.
In addition to supporting the health and well-being of lactating mothers and babies, the collaboration is a step towards the betterment of women’s health in India and across the world.
The novel Areola cream contains ultra-pure lanolin, a natural moisturising waxy substance derived from Australian sheep wool, to provide soothing protection for the sore and delicate skin on the breasts.
In a press release, Akums said: “The ultra-pure lanolin used in the cream is non-sensitizing and hypoallergenic, which makes it completely natural and safe for babies.”
The nipple cream is dermatologically tested and safe for the mother’s skin as well as the baby’s oral health during lactation due to its colourless and tasteless nature.
Furthermore, the care product is enriched with different soothing ingredients that nurture the nipple and adjoining breast skin, provides skin softness, and soothes irritation.
Some studies suggest that nearly 90 % of women develop nipple soreness and pain during breastfeeding.
Moreover, many nursing mothers stop breastfeeding after one week due to the pain of cracked nipples.
The common factors associated with cracked nipples include poor positioning of the baby on the breast, abrupt detachment of the baby after feeding, skin sensitivity, hormonal changes causing breast tenderness, and climate variability.
Breast milk is an important source of energy and nutrients in children 6-23 months and it contains antibodies that help babies fight off viruses and bacteria while lowering the baby’s risk of having asthma or allergies.
Through the Akums-Fermenta Biotech partnership, the soon-to-launch Areola cream acts as an emollient and occlusive moisturiser that replenishes stratum corneum lipids and reduces the signs and symptoms of clinically dry and cracked skin.
The collaboration aligns with Akums’ commitment to integrating value-added quality and leveraging partnerships with innovative Research &Development (R&D) companies to better serve its clients and patients around the world.
It comes barely a week after Akums partnered with Lyrus Life Sciences to develop patented technologies and manufacturing products for global markets.
The unique treatments and therapies emerging from this world-class collaboration will ensure the launch of patented drugs and more patient-friendly formulations that are beneficial for patients.
In December 2022, Akums partnered with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for the research and development of a range of products for multiple therapies.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
